Therapeutic approach of histamine H3 receptors in obesity

Recent Patents on CNS Drug Discovery

Volumn 2, Issue 3, 2007, Pages 238-240

  Masaki, Takayuki ^a   Yoshimatsu, Hironobu ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Histamine; Histamine H1 receptors; Histamine H3 receptors; Obesity

Indexed keywords

A 331440; A 423579; ADIPOCYTOKINE; ALPHA METHYLHISTAMINE; ANTIOBESITY AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPHENIRAMINE; CIPROXIFAN; CLOBENPROPIT; CYTOKINE; GT 2394; HISTAMINE; HISTAMINE H1 RECEPTOR AGONIST; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; HORMONE; IMETIT; IMIDAZOLE DERIVATIVE; IMMEPIP; LEPTIN; NEUROLEPTIC AGENT; NNC 38 1049; NNC 38 1202; PROXYFAN; THIOPERAMIDE; UNCLASSIFIED DRUG;

CLINICAL PROTOCOL; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; FOOD INTAKE; HUMAN; METABOLIC DISORDER; NONHUMAN; OBESITY; PATENT; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RISK FACTOR;

ANIMALS; HISTAMINE; HISTAMINE ANTAGONISTS; HUMANS; OBESITY; RECEPTORS, HISTAMINE H3;

EID: 36749009798     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488907782411792     Document Type: Review

References (54)

1. Brown RE, Sevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001; 63: 637-672.
2. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003; 4: 121-130.
3. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M. Histaminergic transmission in the mammalian brain. Physiol Rev 1991; 71: 1-51.
4. Terao A, Steininger TL, Morairty SR, Kilduff TS. Age-related changes in histamine receptor mRNA levels in the mouse brain. Neurosci Lett 2004; 355: 81-84.
5. Timmerman H. Cloning of the H1 histamine receptor. Trends Pharmacol Sci 1992; 13: 6-7.
6. Birdsall NJ. Cloning and structure-function of the H2 histamine receptor. Trends Pharmacol Sci 1991; 12: 9-10.
7. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832-837.
8. Nguyen T, Shapiro DA, George SR, et al. Discovery of a novel member of the histamine receptor family. Mol Pharmacol 2001; 59: 427-433.
9. de Esch IJ, Thurmond RL, Jongejan A, Leurs R. The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 2005; 26: 462-469.
10. 3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 2001; 59: 1-8.
11. 3) visualized in the brain of human and non-human primates. Brain Res 1990; 526: 322-327.
12. Leurs F, Bakker RA, Timmerman H, de Esch IJ. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 2005; 4: 107-120.
13. Hancock AA, Brune ME. Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Expert Opin Investig Drugs 2005; 14: 223-241.
14. Tokita S, Takahashi K, Kotani H. Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci 2006; 101: 12-18.
15. Esbenshade TA, Fox OB, Cowart MD. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv 2006; 6: 77-88.
16. Celanire S, Wijtmans M, Talagat P, Leurs R, de Esch IJ. histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today 2005; 10: 1613-1627.
17. Cowart M, Altenbach R, Black L, Faghih R, Zhao C, Hancock AA. Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists. Mini Rev Med Chem 2004; 4: 979-992.
18. Passani MB, Lin JS, Hancock A, Crochet S, Blandina P. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004; 25: 618-625.
19. Ahima RS. Central actions of adipocyte hormones. Trends Endocrinol Metab 2005; 16: 307-313.
20. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350.
21. Unger RH. The hyperleptinemia of obesity-regulator of caloric surpluses. Cell 2004; 117: 145-146.
22. Friedman JM. Modern science versus the stigma of obesity. Nat Med 2004; 10: 563-569.
23. Bouret SG, Simerly RB. Minireview: leptin and development of hypothalamic feeding circuits. Endocrinology 2004; 145: 2621-2616.
24. Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res 2004; 59: 287-304.
25. Takahashi KA, Cone RD. Fasting induces a large, leptin-dependent increase in the intrinsic action potential frequency of orexigenic arcuate nucleus NPY/AgRP neurons. Endocrinology 2005; 146: 1043-1047.
26. Balthasar N, Coppari R, McMinn J, et al. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron 2004; 42: 983-991.
27. Yoshimatsu H, Itateyama E, Kondou S, et al. Hypothalamic neuronal histamine as a target of leptin in feeding behavior. Diabetes 1999; 48: 2286-2291.
28. Morimoto T, Yamamoto Y, Yamatodani A. Leptin facilitates histamine release from the hypothalamus in rats. Brain Res 2000; 868: 367-369.
29. Morimoto T, Yamamoto Y, Mobarakeh JI, et al. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav 1999; 67: 679-683.
30. Masaki T, Yoshimatsu H. The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharmacol Sci 2006; 27: 279-284.
31. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Central infusion of histamine reduces fat accumulation and up-regulatcs UCP family in leptin resistant obese mice. Diabetes 2001; 50: 376-384.
32. Kasaoka S, Tsuboyama-Kasaoka N, Kawahara Y, et al. Histidine supplementation suppresses food intake and fat accumulation in rats. Nutrition 2004; 20: 991-996.
33. Fulop AK, Foldes A, Buzas E, et al. Hyperleptinemia, visceral adiposity, and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene. Endocrinology 2003; 144: 4306-4314.
34. Jorgensen EA, Vogelsang TW, Knigge U, Watanabe T, Warberg J, Kjaer A. Increased susceptibility to diet-induced obesity in histamine-deficient mice. Neuroendocrinology 2006; 83: 289-294.
35. 1-receptor in the regulation of feeding rhythm and obesity. Diabetes 2004; 53: 2250-2260.
36. Takahashi K, Suwa H, Ishikawa T, Kotani H. Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J Clin Invest 2002; 110: 1791-1799.
37. Yoshimoto, R., Ishihara, A., Kanatani, A., Tokita, S.: WO07032536 (2007).
38. Morimoto T, Yamamoto Y, Yamatodani A. Brain histamine and feeding behavior. Behav Brain Res 2001; 124: 145-150.
39. 3 receptor antagonist on hypothalamic neural activity, food intake and body weight. Int J Obes (Lond) 2005; 29: 1402-1412.
40. Malmlöf K, Golozoubova V, Peschke B, et al. Increase of neuronal histamine in obese rats is associated with decreases in body weight and plasma triglycerides. Obesity (Silver Spring) 2006; 14: 2154-2162.
41. Yoshimatsu H, Chiba S, Tajima D, Akehi Y, Sakata T. Histidine suppresses food intake through its conversion into neuronal histamine. Exp Biol Med (Maywood) 2002; 227: 63-68.
42. Tuomisto L, Yamatodani A, Jolkkonen J, Sainio EL, Airaksinen MM. Inhibition of brain histamine synthesis increases food intake and attenuates vasopressin response to salt loading in rats. Methods Find Exp Clin Pharmacol 1994; 16: 355-359.
43. Lecklin A, Etu-Seppala P, Stark H, Tuomisto L. Effects of intracerebro-ventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats. Brain Res 1998; 793: 279-288.
44. Sakata T, Ookuma K, Fukagawa K, et al. Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation. Brain Res 1988; 441: 403-407.
45. Mollet A, Lutz TA, Meier S, Riediger T, Rushing PA, Scharrer E. Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1442-1448.
46. 1 histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychpharmacology 2003; 28: 519-526.
47. Itoh E, Fujimiya M, Inui A. Thioperamide, a histamine H3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats. Biol Psychiatry 1999; 45: 475-481.
48. Attoub S, Moizo L, Sobhani I, Laigneau JP, Lewin MJ, Bado A. The H3 receptor is involved in cholecystokinin inhibition of food intake in rats. Life Sci 2001; 69: 469-478.
49. Sindelar DK, Shepperd ML, Pickard RT, et al. Central H3R activation by thioperamide does not affect energy balance. Pharmacol Biochem Behav 2004; 78: 275-283.
50. Yoshimoto R, Miyamoto Y, Shimamura K, et al. Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci USA 2006; 103: 13866-13871.
51. 3 receptors. Mol Pharmacol 2002; 62, 389-397.
52. Yates SL, Powlowski GP, Babu JS, Rajagopalan R, Wawro WJ, Tedford CE. Inverse agonists of the histamine-3 receptor as appetite suppressants. Abstract of the American Chemical Society. New Orleans, LA (2003).
53. 3 receptor antagonist. Eur J Pharmacol 2004; 487: 183-197.
54. 3R) antagonist analogs of A-331440 with improved safety and efficacy. Inflamm Res 2005; 54 (Suppl 1): S27-29.